<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836327</url>
  </required_header>
  <id_info>
    <org_study_id>MS and NMOSD-ChinaPLAGH</org_study_id>
    <nct_id>NCT02836327</nct_id>
  </id_info>
  <brief_title>Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders</brief_title>
  <official_title>Multimodel MRI to Explore the Pathophysiology of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate multimodel MRI exploring the pathophysiology of multiple sclerosis and&#xD;
      neuromyelitis optica spectrum disorders.&#xD;
&#xD;
      The investigators use multimodel MRI to evaluate the extent of blood-brain barrier and white&#xD;
      matter fiber tracts destruction , iron deposition and cerebral blood flow of associated&#xD;
      regions in multiple sclerosis and neuromyelitis optica spectrum disorders using&#xD;
      contrast-enhanced magnetic resonance imaging , quantitative susceptibility mapping, diffusion&#xD;
      tension imaging, and arterial spin labeling with post labeling delay of 2.0 seconds. Transfer&#xD;
      constant volume , magnetic susceptibility, cerebral blood flow and fractional anisotropy(FA)&#xD;
      value were measured in lesion and normal appearing white matter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients:&#xD;
&#xD;
      Patients with multiple sclerosis and neuromyelitis optica spectrum disorders were included.&#xD;
      clinical characteristics such as disease duration, expanded disability status scale(EDSS)&#xD;
      score, age, associated laboratory examination(autoantibodies directed to aquaporin-4 and&#xD;
      oligoclonal bands in serum as well as cerebrospinal fluid)were recorded.&#xD;
&#xD;
      Imaging scan were conducted at admission, six months and one year after admission&#xD;
&#xD;
      Imaging protocols:&#xD;
&#xD;
      MRI scan protocols: T2 weighted image, T1 weighted image, Diffusion weighted image(DWI),&#xD;
      fluid-attenuated inversion recovery(FLAIR), dynamic contrast-enhanced magnetic resonance&#xD;
      imaging(DCE-MRI) , diffusion tension imaging(DTI) ,quantitative susceptibility mapping(QSM) ,&#xD;
      arterial spin labeling(ASL) with post labeling delay(PLD) of seconds, sagittal CUBE Fluid&#xD;
      Attenuation Inversion Recovery (FLAIR) images, sagittal 3-dimensional Fast Spoiled Gradient&#xD;
      Echo(3D-FSPGR).&#xD;
&#xD;
      Contrast agent:&#xD;
&#xD;
      Omniscan 0.1mmol/kg, Inject rate：2ml/s&#xD;
&#xD;
      Imaging evaluation:&#xD;
&#xD;
      Transfer constant volume value measured by DCE-MRI indicates the extent of blood-brain&#xD;
      barrier destruction.&#xD;
&#xD;
      Magnetic susceptibility manifests iron deposition in lesions and normal appearing white&#xD;
      matter.&#xD;
&#xD;
      Diffusion tension imaging demonstrates the extent of white matter fiber tracts destruction.&#xD;
&#xD;
      Arterial spin labeling(ASL) with post labeling delay(PLD)of seconds shows cerebral blood flow&#xD;
      in associated regions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence</measure>
    <time_frame>three months to one year</time_frame>
    <description>The patients will be monitored whether they recured multiple sclerosis and neuromyelitis optica spectrum disorders confirmed by neurologist and conventional MRI.&#xD;
Clinical suspicious signs of recurrence : visual loss,urination and defecation function disturbance and so on.&#xD;
Conventional MRI: there are new lesions or the lesions show high signal on diffusion weighted images or enhancement on post contrast enhanced images.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Neuromyelitis Optica Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Multiple sclerosis</arm_group_label>
    <description>Multiple sclerosis patients confirmed by neurologist according to the 2010 revised Mcdonald criteria without other nervous system diseases.All patients performed magnetic resonance imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuromyelitis optica spectrum disorders</arm_group_label>
    <description>Neuromyelitis optica spectrum disorders confirmed by neurologist according to the 2015 revised diagnostic criteria without other nervous system diseases.All patients performed magnetic resonance imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health control</arm_group_label>
    <description>Health control is defined as no other nervous system diseases such as ischemic stroke, alzheimer disease and so on. The baseline data(age,education background etc.) is similar to multiple sclerosis and neuromyelitis optica spectrum disorders patients.All participants performed magnetic resonance imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Magnetic Resonance Imaging</description>
    <arm_group_label>Health control</arm_group_label>
    <arm_group_label>Multiple sclerosis</arm_group_label>
    <arm_group_label>Neuromyelitis optica spectrum disorders</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with multiple sclerosis (according to the 2010 revised Mcdonald criteria) and&#xD;
        neuromyelitis optica spectrum disorders (according to the 2015 revised diagnostic criteria)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. a diagnosis of neuromyelitis optica spectrum disorders(according to the 2015 revised&#xD;
             diagnostic criteria) or relapsing remitting multiple sclerosis(according to the 2010&#xD;
             revised Mcdonald criteria)&#xD;
&#xD;
          2. age between 18 years old and 60 years old(concluding 18 years old and 60 years old)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. common exclusion for MRI such as patients with claustrophobia&#xD;
&#xD;
          2. patients with poor imaging quality（Poor imaging quality mainly defined as the image&#xD;
             cannot be applied to future analysis on account of severe motion artifacts appeared in&#xD;
             conventional MRI and mistakes in the MRI process by accident factors which cannot to&#xD;
             be applied to future analysis）&#xD;
&#xD;
          3. patients with taking amount of antidepressant recently and with alcoholism and other&#xD;
             nervous system diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Lou, M.D.,Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoxiao Ma, M.D.</last_name>
    <phone>+86 13323326150</phone>
    <email>1103483781@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jinhao Lyu, M.D.</last_name>
    <email>lvjinhao@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinhao Lyu, BS</last_name>
      <phone>+8613391851857</phone>
      <email>lvjinhao@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>July 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>August 7, 2016</last_update_submitted>
  <last_update_submitted_qc>August 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Xin Lou</investigator_full_name>
    <investigator_title>Deputy Chief</investigator_title>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Neuromyelitis Optica Spectrum Disorders</keyword>
  <keyword>Multimodel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuromyelitis Optica</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

